Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
AstraZeneca
Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Last Updated: March 26, 2023

Gilead Sciences Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Gilead Sciences Inc
International Patents:2032
US Patents:79
Tradenames:18
Ingredients:18
NDAs:23
Drug Master File Entries: 7
Patent Litigation for Gilead Sciences Inc: See patent lawsuits for Gilead Sciences Inc

Drugs and US Patents for Gilead Sciences Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead Sciences Inc ODEFSEY emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate TABLET;ORAL 208351-001 Mar 1, 2016 RX Yes Yes 7,125,879 See Plans and Pricing Y Y See Plans and Pricing
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes 9,868,745 See Plans and Pricing Y Y See Plans and Pricing
Gilead Sciences Inc HARVONI ledipasvir; sofosbuvir TABLET;ORAL 205834-001 Oct 10, 2014 RX Yes Yes See Plans and Pricing See Plans and Pricing
Gilead Sciences Inc HARVONI ledipasvir; sofosbuvir PELLETS;ORAL 212477-001 Aug 28, 2019 RX Yes No 9,284,342*PED See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Gilead Sciences Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gilead Sciences Inc VEMLIDY tenofovir alafenamide fumarate TABLET;ORAL 208464-001 Nov 10, 2016 7,803,788 See Plans and Pricing
Gilead Sciences Inc DESCOVY emtricitabine; tenofovir alafenamide fumarate TABLET;ORAL 208215-001 Apr 4, 2016 6,703,396*PED See Plans and Pricing
Gilead Sciences Inc VIREAD tenofovir disoproxil fumarate TABLET;ORAL 021356-001 Oct 26, 2001 4,808,716 See Plans and Pricing
Gilead Sciences Inc ZYDELIG idelalisib TABLET;ORAL 205858-001 Jul 23, 2014 8,138,195 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for GILEAD SCIENCES INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 300 mg ➤ Subscribe 2010-01-26
➤ Subscribe Tablets 200 mg/25 mg/300 mg ➤ Subscribe 2015-05-20
➤ Subscribe Tablets 150 mg ➤ Subscribe 2015-12-09
➤ Subscribe Tablets 150 mg, 200 mg, and 250 mg ➤ Subscribe 2012-05-17
➤ Subscribe Tablets 150 mg, 150 mg, 200 mg, 300 mg ➤ Subscribe 2018-10-04

Supplementary Protection Certificates for Gilead Sciences Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2487166 380 3-2017 Slovakia See Plans and Pricing PRODUCT NAME: KOBICISTAT VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM/TENOFOVIR ALAFENAMID VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/15/1061 20151123
2430014 2016C/006 Belgium See Plans and Pricing PRODUCT NAME: LEDIPASVIR/SOFOSBUVIR; AUTHORISATION NUMBER AND DATE: EU/1/14/958 20141118
1564210 CA 2013 00058 Denmark See Plans and Pricing PRODUCT NAME: ELVITEGRAVIR I ENHVER FORM SOM ER OMFATTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/13/830/001-002 20130524
2595980 53/2020 Austria See Plans and Pricing PRODUCT NAME: REMDESIVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ ODER ESTER DAVON; REGISTRATION NO/DATE: EU/1/20/1459 (MITTEILUNG) 20200703
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Boehringer Ingelheim
Express Scripts
Dow
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.